Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Cited by 56 Publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Mol Cell, 2019, 75(4):823-834

PubMed: 31302001 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5043

PubMed: 31695040 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):737

PubMed: 31570706 ( click the link to review the publication )

Cells, 2019, 8(8)

PubMed: 31370342 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:2050183

PubMed: 31178953 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29283

PubMed: 31595984 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(2):220-233

PubMed: 31516744 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5637

PubMed: 30948782 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(2):312-324

PubMed: 30745823 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 371:63-73

PubMed: 30953615 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):102

PubMed: 30678647 ( click the link to review the publication )

Exp Eye Res, 2019, 189:107821

PubMed: 31589841 ( click the link to review the publication )

J Natl Cancer Inst, 2018, 110(4):390-399

PubMed: 29202196 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(6):2199-2215

PubMed: 29975948 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):1051-1060

PubMed: 29440291 ( click the link to review the publication )

Mycoses, 2018, 61(11):853-856

PubMed: 29998564 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

EMBO J, 2017, 36(5):646-663

PubMed: 28093501 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )
Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(3):543-554

PubMed: 27592300 ( click the link to review the publication )

Sci Rep, 2017, 7(1):4546

PubMed: 28674407 ( click the link to review the publication )

Am J Transl Res, 2017, 9(11):4945-4953

PubMed: 29218092 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2219-2226

PubMed: 28458565 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Cell, 2017, 170(5):845-859

PubMed: 28823557 ( click the link to review the publication )

Nat Commun, 2016, 7:13122

PubMed: 27959342 ( click the link to review the publication )

Cancer Res, 2016, 76(4):965-73

PubMed: 26676744 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Biochem J, 2016, 473(12):1733-44

PubMed: 27059856 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(17):14796-813

PubMed: 26142707 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Mol Cancer, 2014, 15:30

PubMed: 24927996 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805 ( click the link to review the publication )

Exp Gerontol, 2014, 52:55-69

PubMed: 24486130 ( click the link to review the publication )

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629 ( click the link to review the publication )

Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213 ( click the link to review the publication )

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801 ( click the link to review the publication )
Sci Transl Med, 2012, 4(120):120ra17

PubMed: 22277784 ( click the link to review the publication )

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003 ( click the link to review the publication )

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451 ( click the link to review the publication )

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234 ( click the link to review the publication )

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504 ( click the link to review the publication )

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXDWpFKSzVyPUCuNFAxOzB\|IN88US=>	M3qxUHNCVkeHUh?=
IST-MEL1	M3jPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMECwOFA4KM7:TR?=	NVv3NXp5W0GQR1XS
NCI-SNU-1	M3\JfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMECyNFch\|ryP	Ml7UV2FPT0WU
FADU	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMECyNFkh\|ryP	M1fMTXNCVkeHUh?=
C32	Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LCcmlEPTB;MD6wNFMxPCEQvF2=	NYflO\|I1W0GQR1XS
D-566MG	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\mOWdKUUN3ME2wMlAxOzlizszN	MoT2V2FPT0WU
LXF-289	M{T2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMEC0NVkh\|ryP	Mn\GV2FPT0WU
HGC-27	M3[5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrHZ3BKSzVyPUCuNFA2OSEQvF2=	M4O0dnNCVkeHUh?=
RPMI-7951	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMEC3NVch\|ryP	MYHTRW5ITVJ?
HSC-3	M{L6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{P2OmlEPTB;MD6wNFkzQSEQvF2=	NUHu[lRnW0GQR1XS
MIA-PaCa-2	NYfHXmpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmriTWM2OD1yLkCxNFA6KM7:TR?=	MoTIV2FPT0WU
KS-1	M3;qb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHITWM2OD1yLkCxN\|U2KM7:TR?=	MUDTRW5ITVJ?
CAL-51	NI\DbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXUTndpUUN3ME2wMlAyPDB3IN88US=>	M4i1THNCVkeHUh?=
MDA-MB-361	MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMEG0PVUh\|ryP	NH\UO3BUSU6JRWK=
TI-73	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPXTWM2OD1yLkCxO\|k3KM7:TR?=	MYHTRW5ITVJ?
AGS	M1;Nbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XqPWlEPTB;MD6wNVk{QCEQvF2=	M3jTd3NCVkeHUh?=
NCI-H460	MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHHWHQ5UUN3ME2wMlAyQTd2IN88US=>	NW\kT4tVW0GQR1XS
A204	NVGxcG9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDQTWM2OD1yLkCyNlQ6KM7:TR?=	M36zcXNCVkeHUh?=
CHL-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTTTWM2OD1yLkCyNlUyKM7:TR?=	M172SHNCVkeHUh?=
DU-4475	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDoTWM2OD1yLkCyNlYyKM7:TR?=	Ml63V2FPT0WU
CGTH-W-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTiXJJpUUN3ME2wMlAzOzR7IN88US=>	NIS0WVBUSU6JRWK=
HCC2218	M121bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPiR41KSzVyPUCuNFI1QTRizszN	MV3TRW5ITVJ?
A2780	NHvX[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\jW4VKSzVyPUCuNFI2OzFizszN	NH34V4pUSU6JRWK=
NCI-H720	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPRWJFSUUN3ME2wMlAzPTR4IN88US=>	MlqxV2FPT0WU
NCI-N87	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PXNWlEPTB;MD6wNlU6OyEQvF2=	MlHIV2FPT0WU
CHP-212	M3HNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMEK2Nlgh\|ryP	NUOydpMzW0GQR1XS
NCI-H23	NX7ucoFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfCW2pKSzVyPUCuNFI3PjVizszN	M2PnVHNCVkeHUh?=
D-263MG	MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzPb2dXUUN3ME2wMlAzPzh4IN88US=>	MmmxV2FPT0WU
ME-180	NWHF[mpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DDS2lEPTB;MD6wNlg6OSEQvF2=	NYnNXlNTW0GQR1XS
SW982	NX:5XGhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TBPGlEPTB;MD6wNlk6QSEQvF2=	NGrWe4lUSU6JRWK=
OE19	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXRTWM2OD1yLkCzNFc4KM7:TR?=	MWnTRW5ITVJ?
SK-LU-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTBwMEOwPFIh\|ryP	M3LqTnNCVkeHUh?=
H4	M2DyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnj3TWM2OD1yLkCzNFkh\|ryP	NIqx[pZUSU6JRWK=
HT-144	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMEOwPVMh\|ryP	NIL5c4pUSU6JRWK=
SK-UT-1	NV\WSo1TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDvNHNKSzVyPUCuNFMyPzhizszN	MYjTRW5ITVJ?
D-336MG	MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnNdlh7UUN3ME2wMlA{OzB7IN88US=>	M{[wTXNCVkeHUh?=
MDA-MB-175-VII	Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33qSGlEPTB;MD6wN\|M2PCEQvF2=	NIPrbZBUSU6JRWK=
GAMG	MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMEO0N\|Uh\|ryP	NXThS5gzW0GQR1XS
CP50-MEL-B	NVL3Z5E6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\vW2lEPTB;MD6wN\|Q2KM7:TR?=	Mmj6V2FPT0WU
OVCAR-5	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jrW2lEPTB;MD6wN\|Q5KM7:TR?=	M4PafHNCVkeHUh?=
SK-MES-1	NX7p[GZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMEO2NFYh\|ryP	NF20[HhUSU6JRWK=
VM-CUB-1	NELxc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4GwU2lEPTB;MD6wN\|Y2PyEQvF2=	NXjV[\|R1W0GQR1XS
WM-115	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PXTmlEPTB;MD6wN\|c3OiEQvF2=	MoXsV2FPT0WU
DSH1	NGHpOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\TOHg6UUN3ME2wMlA{QDB5IN88US=>	M4f2cnNCVkeHUh?=
Becker	M332T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLweI8zUUN3ME2wMlA{QDh3IN88US=>	NWXvWmpLW0GQR1XS
SW962	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMEO5OFUh\|ryP	NUXPcGFJW0GQR1XS
TYK-nu	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DuNWlEPTB;MD6wN\|k5PSEQvF2=	NHjpeJFUSU6JRWK=
HO-1-N-1	NIXOR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPTTWM2OD1yLkC0NFIyKM7:TR?=	MV\TRW5ITVJ?
T98G	NE\3RW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1K4XGlEPTB;MD6wOFExOyEQvF2=	MVnTRW5ITVJ?
ACN	NFjOU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofhTWM2OD1yLkC0NVYzKM7:TR?=	MXPTRW5ITVJ?
SW780	MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHDTlNmUUN3ME2wMlA1OjB\|IN88US=>	NY\sOZd{W0GQR1XS
Detroit562	M3KzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMESyN\|kh\|ryP	NHvhd4FUSU6JRWK=
BB49-HNC	NEX6UoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jjT2lEPTB;MD6wOFI1OyEQvF2=	M4Pye3NCVkeHUh?=
HN	NVXaTG1YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTBwMESyO\|Ih\|ryP	MYrTRW5ITVJ?
H9	NGDuOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvVVVBKSzVyPUCuNFQ{PzFizszN	NH7uO5ZUSU6JRWK=
VA-ES-BJ	NF;pUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\VN4pPUUN3ME2wMlA1PDR5IN88US=>	M1u0NXNCVkeHUh?=
MEL-JUSO	M3X6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfROmhKSzVyPUCuNFQ1PzVizszN	MVvTRW5ITVJ?
BT-474	M{K5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMES1JO69VQ>?	Ml72V2FPT0WU
CaR-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1S3N2lEPTB;MD6wOFU1QSEQvF2=	NGi4ZpBUSU6JRWK=
PSN1	M3;WR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\NTWM2OD1yLkC0OlA{KM7:TR?=	MlfOV2FPT0WU
KYSE-510	M1PLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMES2OFkh\|ryP	NUH5cppuW0GQR1XS
KP-4	NV:xSJVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojOTWM2OD1yLkC0O\|U{KM7:TR?=	MVzTRW5ITVJ?
KYSE-410	NYj1OlZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPpbo5[UUN3ME2wMlA1Pzd{IN88US=>	M{LVNXNCVkeHUh?=
G-402	M3i5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVL6bWlPUUN3ME2wMlA1Pzh7IN88US=>	M4H1PHNCVkeHUh?=
DOK	M4Sxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3[0TWlEPTB;MD6wOFkxOiEQvF2=	NF7HWI9USU6JRWK=
COR-L88	M2\PWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMES5NVIh\|ryP	NE\Pe\|dUSU6JRWK=
SKG-IIIa	NWPYWIpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfVZo9KSzVyPUCuNFQ6QDZizszN	MlTIV2FPT0WU
AN3-CA	NVrhcJlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4f4RWlEPTB;MD6wOUDPxE1?	NIHRN3VUSU6JRWK=
SW48	M2Dldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3nUGFEUUN3ME2wMlA2ODN7IN88US=>	NX:5dFhoW0GQR1XS
YKG-1	NVjwc4djT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXKTWM2OD1yLkC1NFcyKM7:TR?=	M4\p[HNCVkeHUh?=
KYSE-150	Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LtVmlEPTB;MD6wOVI{PSEQvF2=	M3\4c3NCVkeHUh?=
HuO-3N1	M4XXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwMEWyN\|ch\|ryP	MX3TRW5ITVJ?
LB1047-RCC	NFjWbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVeyfpRPUUN3ME2wMlA2Ojl4IN88US=>	M4G1UnNCVkeHUh?=
NCI-H2030	Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDkTWM2OD1yLkC1OFE1KM7:TR?=	NF6yVYRUSU6JRWK=
YH-13	M{HTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwMEW3NlIh\|ryP	MofpV2FPT0WU
5637	MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMEW3OEDPxE1?	MnPlV2FPT0WU
LOXIMVI	M2nSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rkSGlEPTB;MD6wOVg4OiEQvF2=	NV;FXGhxW0GQR1XS
GT3TKB	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIe1T3BKSzVyPUCuNFU6PDJizszN	MkjXV2FPT0WU
TCCSUP	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMEW5OlQh\|ryP	MY\TRW5ITVJ?
EPLC-272H	NYOwbVFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDseod{UUN3ME2wMlA3OjB3IN88US=>	MkeyV2FPT0WU
LU-99A	MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwME[yN\|ch\|ryP	M2HURnNCVkeHUh?=
NCI-H1755	NV3GU\|NRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwME[zOFEh\|ryP	NW\PR\|dKW0GQR1XS
KM12	NHuzPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4iyXWlEPTB;MD6wOlM1QCEQvF2=	M{TQUnNCVkeHUh?=
SF295	MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwME[0OVIh\|ryP	NWDMZ2dWW0GQR1XS
MZ2-MEL	M4\0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDlTpFsUUN3ME2wMlA3PTV\|IN88US=>	MkP6V2FPT0WU
HEC-1	NXzxdZhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDNTWM2OD1yLkC2OVg5KM7:TR?=	NGD6eGZUSU6JRWK=
SW684	NGTSdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2Tw[WlEPTB;MD6wOlU6OSEQvF2=	M2rMe3NCVkeHUh?=
SF539	M2rCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3tSmZKSzVyPUCuNFY3QDFizszN	NYnhV5M{W0GQR1XS
GMS-10	NIXFWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\iXWlEPTB;MD6wOlY6QSEQvF2=	NVTVOGt6W0GQR1XS
MV-4-11	NF\NVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvFfJRwUUN3ME2wMlA3QDB\|IN88US=>	NE\DbpJUSU6JRWK=
HT-29	MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PFVWlEPTB;MD6wOlkyQSEQvF2=	NIDn[\|FUSU6JRWK=
23132-87	Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXWPYZKSzVyPUCuNFY6PSEQvF2=	Mn72V2FPT0WU
SW620	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLmTWM2OD1yLkC3NFI3KM7:TR?=	NXnHepBnW0GQR1XS
HCC1806	NWGzNppyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjKUmVKSzVyPUCuNFcyOzFizszN	M1[5OHNCVkeHUh?=
Hs-578-T	MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnITWM2OD1yLkC3NlA5KM7:TR?=	NUnkVWtTW0GQR1XS
A2058	NIXpcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DmdmlEPTB;MD6wO\|IzQCEQvF2=	MlX5V2FPT0WU
MEL-HO	MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37pNGlEPTB;MD6wO\|I2PSEQvF2=	NEfORWxUSU6JRWK=
HCC2998	MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwMEezOFch\|ryP	M4P1O3NCVkeHUh?=
HuO9	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TsOWlEPTB;MD6wO\|U5QSEQvF2=	M{[xOXNCVkeHUh?=
CAL-39	M4TUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMEe3OlYh\|ryP	NIDyNpRUSU6JRWK=
M14	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwMEe5NVMh\|ryP	MnPRV2FPT0WU
BFTC-909	MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XCOWlEPTB;MD6wO\|k3QSEQvF2=	M3TFe3NCVkeHUh?=
TE-11	M4LDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwMEe5PVYh\|ryP	NEHj[lVUSU6JRWK=
TGBC1TKB	MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLnTWM2OD1yLkC4NFQ{KM7:TR?=	MoDnV2FPT0WU
L-363	NIjacW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInKfnVKSzVyPUCuNFgzODZizszN	M{i2ZnNCVkeHUh?=
A431	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTrTWM2OD1yLkC4NlEh\|ryP	NFHTe4dUSU6JRWK=
MKN45	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwMEiyNVkh\|ryP	MkDlV2FPT0WU
HT-1080	M3HmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwMEi0N\|kh\|ryP	NFfadIFUSU6JRWK=
OVCAR-8	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwMEi2NlIh\|ryP	NV\PVJd{W0GQR1XS
LCLC-97TM1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmq1TWM2OD1yLkC4O\|I5KM7:TR?=	MnPGV2FPT0WU
M059J	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLlRox6UUN3ME2wMlA6ODJ5IN88US=>	NETwbnRUSU6JRWK=
SK-MEL-2	NUfJZWJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwMEmwOkDPxE1?	NVLwOplQW0GQR1XS
TE-1	M1W1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmezTWM2OD1yLkC5NlA1KM7:TR?=	NYH0elBnW0GQR1XS
KYSE-180	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\pOHJKSzVyPUCuNFkzPjJizszN	MVrTRW5ITVJ?
D-247MG	M{jI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXhSlNKSzVyPUCuNFk1PTVizszN	NGjHem5USU6JRWK=
8-MG-BA	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXLdoFKSzVyPUCuNFk1PzJizszN	MkjlV2FPT0WU
NCI-H1792	MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TuWWlEPTB;MD6wPVYyQCEQvF2=	NUnmNYlCW0GQR1XS
MCF7	M1TpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnP3TWM2OD1yLkC5Olc4KM7:TR?=	M1rFbnNCVkeHUh?=
NCI-H2122	MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkX1TWM2OD1yLkC5O\|Q2KM7:TR?=	MXPTRW5ITVJ?
EFO-27	MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrJTWM2OD1yLkC5PVk4KM7:TR?=	MVrTRW5ITVJ?
LB2241-RCC	M1KwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMUCwOVQh\|ryP	NYfDXZE1W0GQR1XS
SN12C	M3fNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHRblNKSzVyPUCuNVAyODdizszN	NWTXbWtpW0GQR1XS
A498	MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XrUmlEPTB;MD6xNFE5KM7:TR?=	MnLVV2FPT0WU
PANC-03-27	Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHZVIlRUUN3ME2wMlExOjh4IN88US=>	M3nVWXNCVkeHUh?=
NCI-H1581	NW\OWWNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\BfldKSzVyPUCuNVAzQSEQvF2=	NHXKdo5USU6JRWK=
U-87-MG	NYfSe4FpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DsT2lEPTB;MD6xNFMxPyEQvF2=	NFyyRWlUSU6JRWK=
G-401	NYWy[GQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMUCzOVMh\|ryP	NWfZTJVrW0GQR1XS
SiHa	MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfTTWM2OD1yLkGwOFg3KM7:TR?=	NF\OdJVUSU6JRWK=
U251	NEPuNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrHPZJKSzVyPUCuNVA2OjVizszN	NEXOXWxUSU6JRWK=
MMAC-SF	NVvKNoQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoT2TWM2OD1yLkGwOVMyKM7:TR?=	MkLwV2FPT0WU
BB65-RCC	NFfGb\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwMUC1OVQh\|ryP	M374eHNCVkeHUh?=
NKM-1	NYnQXWZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMUC2OlYh\|ryP	NFXZNWFUSU6JRWK=
HD-MY-Z	NWDQT5dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMUC4O\|Mh\|ryP	NFTYb4VUSU6JRWK=
TGBC11TKB	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLtRVVKSzVyPUCuNVA6ODNizszN	Mn7aV2FPT0WU
COLO-679	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGOyd4ZKSzVyPUCuNVEzOTFizszN	M3nRUHNCVkeHUh?=
TE-8	MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTBwMUGyOlQh\|ryP	NWDUOoluW0GQR1XS
SK-MEL-28	Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TyfmlEPTB;MD6xNVMzOSEQvF2=	NHuxZWlUSU6JRWK=
SH-4	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DKTGlEPTB;MD6xNVM2PiEQvF2=	NX[ycVZUW0GQR1XS
KALS-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTBwMUGzPVMh\|ryP	NFrIbY9USU6JRWK=
RKO	Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTBwMUG3OlQh\|ryP	NITDOVlUSU6JRWK=
OMC-1	MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMUG3PVch\|ryP	MX7TRW5ITVJ?
BT-549	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkn1TWM2OD1yLkGxO\|k6KM7:TR?=	M4TVRXNCVkeHUh?=
NCI-H28	Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwMUG4NVch\|ryP	NFX1NpRUSU6JRWK=
RXF393	M2\mXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMUG5PFIh\|ryP	MYrTRW5ITVJ?
COLO-829	NUnyeXpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LQN2lEPTB;MD6xNlAxPSEQvF2=	M{PvV3NCVkeHUh?=
HMV-II	Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\MdVdKSzVyPUCuNVIxOiEQvF2=	MWrTRW5ITVJ?
SW1990	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkH0TWM2OD1yLkGyNVU4KM7:TR?=	MlzMV2FPT0WU
NCI-H1437	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIO1VoZKSzVyPUCuNVIyPTdizszN	NFzsSpNUSU6JRWK=
SNB75	NGXXfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nYdWlEPTB;MD6xNlE3QSEQvF2=	Mkj1V2FPT0WU
EW-3	MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHqTWM2OD1yLkGyOlYyKM7:TR?=	NFnMfmxUSU6JRWK=
SAS	MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFS3eYNKSzVyPUCuNVI3QSEQvF2=	M3vnNnNCVkeHUh?=
NCI-H1666	NV63ZmVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMUK3O\|Qh\|ryP	MkTKV2FPT0WU
A375	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\kN5lKSzVyPUCuNVI4PzhizszN	MXrTRW5ITVJ?
CAMA-1	M{jScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PJbWlEPTB;MD6xNlkzPCEQvF2=	MUHTRW5ITVJ?
HuP-T4	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLHNGpKSzVyPUCuNVI6PDNizszN	MoHkV2FPT0WU
NCI-H292	M2TPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDmTWM2OD1yLkGzNVEh\|ryP	M{TsNnNCVkeHUh?=
PC-14	NFjhWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4n1OGlEPTB;MD6xN\|IyOSEQvF2=	MkjSV2FPT0WU
BPH-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwMUO0NUDPxE1?	MlrlV2FPT0WU
GAK	M3XlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zGUGlEPTB;MD6xN\|U3PyEQvF2=	NFzvOnBUSU6JRWK=
VMRC-RCZ	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYn2V3ZoUUN3ME2wMlE{PzZ{IN88US=>	NUS0[ZRYW0GQR1XS
SK-MEL-24	NFXBSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHH3Z4NKSzVyPUCuNVM5PyEQvF2=	NVrMfHNOW0GQR1XS
LB831-BLC	M3HSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHzdFJTUUN3ME2wMlE{QDh\|IN88US=>	NGm4eXRUSU6JRWK=
NCI-H2452	NHzFTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELqdXJKSzVyPUCuNVM6PTZizszN	MnHVV2FPT0WU
RT-112	NFnRSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEO4ZXFKSzVyPUCuNVQxOzVizszN	NGLhWWZUSU6JRWK=
GP5d	M{TQVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnxNGF2UUN3ME2wMlE1OTB2IN88US=>	MXvTRW5ITVJ?
LC-2-ad	M{nLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPGTWM2OD1yLkG0NVIyKM7:TR?=	M3T0PHNCVkeHUh?=
MPP-89	NXn0ZZUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHST4prUUN3ME2wMlE1OTJ3IN88US=>	MnrHV2FPT0WU
NUGC-3	NXrQPHRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjUTWM2OD1yLkG0OFc5KM7:TR?=	MmPUV2FPT0WU
GI-1	NEPnW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHL1TXJKSzVyPUCuNVQ2PThizszN	M1fPR3NCVkeHUh?=
HCC1419	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXtUHJCUUN3ME2wMlE1PTd4IN88US=>	NHLmSINUSU6JRWK=
SW1573	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIruTY5KSzVyPUCuNVQ4PThizszN	M1PGN3NCVkeHUh?=
NCI-H2347	NWLLS5F5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoO5TWM2OD1yLkG0PFM6KM7:TR?=	NID0ZZhUSU6JRWK=
Mewo	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfzN4xKSzVyPUCuNVQ5QDlizszN	MnXlV2FPT0WU
639-V	Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmf5TWM2OD1yLkG1NFE{KM7:TR?=	MVXTRW5ITVJ?
AsPC-1	NVXme5Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIj3cnNKSzVyPUCuNVUzOjVizszN	MX3TRW5ITVJ?
NCI-H1648	NHTmeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXTeo1KSzVyPUCuNVUzOzJizszN	NF3CcZBUSU6JRWK=
786-0	NGO3PHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DxXmlEPTB;MD6xOVM5OSEQvF2=	NF73ZXJUSU6JRWK=
ETK-1	NVHvTnlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LL[WlEPTB;MD6xOVkh\|ryP	NXXLbYcyW0GQR1XS
BxPC-3	MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPIc3VKSzVyPUCuNVU6PjZizszN	NGjRT4lUSU6JRWK=
CAL-62	NYeydlVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfpOXRKSzVyPUCuNVYyPjlizszN	NXr2bWFbW0GQR1XS
HCC1937	NFzpOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nYNmlEPTB;MD6xOlI4PSEQvF2=	M37tTnNCVkeHUh?=
NCI-H1299	NFnNR\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTBwMU[yPFUh\|ryP	NWGz[G1YW0GQR1XS
SW1088	MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMU[0NVMh\|ryP	NE\jOGNUSU6JRWK=
FTC-133	NH\WTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPtbZpIUUN3ME2wMlE3PTRizszN	NIjXV3lUSU6JRWK=
OC-314	NXW4cFFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPKTWM2OD1yLkG2Olkh\|ryP	NHfJWWhUSU6JRWK=
SCC-9	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwMU[3NVYh\|ryP	NXrCUWNmW0GQR1XS
HT-1376	M4fjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfSb3JKSzVyPUCuNVY6OzZizszN	NUfkcm5CW0GQR1XS
U-2-OS	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XNXGlEPTB;MD6xO\|E4OyEQvF2=	Mn\0V2FPT0WU
COLO-824	Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUGySWtuUUN3ME2wMlE4Ojl2IN88US=>	MoPjV2FPT0WU
BB30-HNC	NGjoO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLHTWM2OD1yLkG3N\|Mh\|ryP	MVzTRW5ITVJ?
NCI-H2087	NYjMcGhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2D6UWlEPTB;MD6xO\|M3QCEQvF2=	MX7TRW5ITVJ?
NCI-H2170	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfUPFNPUUN3ME2wMlE4PTN4IN88US=>	MVrTRW5ITVJ?
SK-OV-3	NWThXGpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHjOVdJUUN3ME2wMlE4PTdzIN88US=>	MVjTRW5ITVJ?
MZ7-mel	NHzRTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzwO25KSzVyPUCuNVc3PDlizszN	MlLTV2FPT0WU
NCI-H650	NFi0dI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojFTWM2OD1yLkG3OlgzKM7:TR?=	M4jxeXNCVkeHUh?=
KOSC-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfYelhKSzVyPUCuNVc4OzRizszN	MXrTRW5ITVJ?
SCC-4	NGT2SIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPlbJV1UUN3ME2wMlE4Pzd5IN88US=>	NGfYWG5USU6JRWK=
MDA-MB-157	M2\YWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTsTWM2OD1yLkG4NFgzKM7:TR?=	NWTPXIdxW0GQR1XS
KYSE-520	MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3sTWM2OD1yLkG4NkDPxE1?	M1;FVHNCVkeHUh?=
LK-2	NFT3dotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTLXmRKSzVyPUCuNVg{ODNizszN	NXP0XWc6W0GQR1XS
KNS-81-FD	M33kNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2j4b2lEPTB;MD6xPFM6PCEQvF2=	MWTTRW5ITVJ?
IGROV-1	Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXOySmptUUN3ME2wMlE5PDR\|IN88US=>	NHTJTFhUSU6JRWK=
DEL	M1\xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwMUi0OUDPxE1?	NYjwdXBOW0GQR1XS
NCI-H1395	NWnXV5c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwMUi2PFIh\|ryP	MXvTRW5ITVJ?
JEG-3	M4LQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmS0TWM2OD1yLkG4O\|A2KM7:TR?=	MXXTRW5ITVJ?
BCPAP	Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjNSVNKSzVyPUCuNVg5PzJizszN	M{fX[3NCVkeHUh?=
CAL-27	NUXVNmNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fwPWlEPTB;MD6xPVAzOiEQvF2=	NX;ReHd6W0GQR1XS
RD	NXfmUW43T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLpV4F7UUN3ME2wMlE6OTF\|IN88US=>	Ml7zV2FPT0WU
RVH-421	M2PYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELTZnJKSzVyPUCuNVkyOTZizszN	NWezcnVbW0GQR1XS
Capan-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF7RNldKSzVyPUCuNVkzPTZizszN	NFzCTm9USU6JRWK=
COLO-680N	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwMUmzOlQh\|ryP	M2K5THNCVkeHUh?=
NCI-H1650	M{PuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPwSpVKSzVyPUCuNlAxPTdizszN	M4Ln[HNCVkeHUh?=
SBC-5	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoOxTWM2OD1yLkKwNVE5KM7:TR?=	NEHhe4xUSU6JRWK=
U031	NVm5TlFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwMkC1OFch\|ryP	NEWwVJpUSU6JRWK=
S-117	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;CO3k3UUN3ME2wMlIxPTZ2IN88US=>	NX71b5RIW0GQR1XS
DoTc2-4510	MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMkC3Olkh\|ryP	M4PxcnNCVkeHUh?=
AM-38	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;xTWM2OD1yLkKwPFQ5KM7:TR?=	M1ryWXNCVkeHUh?=
A172	NX;EZVhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwMkGwNlIh\|ryP	MXjTRW5ITVJ?
HPAF-II	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4[0cmlEPTB;MD6yNVI3PCEQvF2=	MXzTRW5ITVJ?
769-P	NEnVOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDMc29XUUN3ME2wMlIyOjhizszN	MmK2V2FPT0WU
MFE-280	NViw[HFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDU[W0xUUN3ME2wMlIyOjl6IN88US=>	MnX5V2FPT0WU
TE-9	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn20TWM2OD1yLkKxO\|g3KM7:TR?=	MX;TRW5ITVJ?
C2BBe1	M1LaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LJSmlEPTB;MD6yNlE6KM7:TR?=	NGHE[3JUSU6JRWK=
EoL-1-cell	M3zlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTrfWtKSzVyPUCuNlIzODNizszN	M2DsT3NCVkeHUh?=
G-361	M{nYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMkK2PFIh\|ryP	NXXRdIRNW0GQR1XS
KYSE-270	NYrqZnpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3aUppKSzVyPUCuNlMxQDRizszN	NV3qc\|RFW0GQR1XS
TK10	MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzVb3pKSzVyPUCuNlMyOTdizszN	Mkn6V2FPT0WU
ML-2	NH75cFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMkOxNVkh\|ryP	M3nMXnNCVkeHUh?=
MHH-ES-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\QZ5dWUUN3ME2wMlI{PjhzIN88US=>	NVL0O296W0GQR1XS
BHY	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETLV3RKSzVyPUCuNlM3QTFizszN	NI\D[XlUSU6JRWK=
LS-513	MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMkO5OlEh\|ryP	NFf2NnlUSU6JRWK=
COLO-678	M2DNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjHW3BKSzVyPUCuNlQxPDRizszN	MUXTRW5ITVJ?
NCI-H747	M2TacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPvPJFKSzVyPUCuNlQyPjlizszN	M2mzbHNCVkeHUh?=
K5	MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFi2VWhKSzVyPUCuNlQ{QCEQvF2=	M3XwO3NCVkeHUh?=
OS-RC-2	NFXWTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTVdlBKSzVyPUCuNlQ2ODlizszN	NH7ibolUSU6JRWK=
KINGS-1	M1P3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjYfGx4UUN3ME2wMlI1PTJ7IN88US=>	NFT6Nm5USU6JRWK=
SCC-25	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;qeYN1UUN3ME2wMlI1PTZ\|IN88US=>	MmX5V2FPT0WU
CAPAN-1	NHHW[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonrTWM2OD1yLkK0O\|g{KM7:TR?=	NV\aU3NMW0GQR1XS
ESS-1	NEXVSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\CTWM2OD1yLkK0PFA2KM7:TR?=	MV;TRW5ITVJ?
TE-6	MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwMkW3OUDPxE1?	NVW2eGVwW0GQR1XS
LB2518-MEL	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:yeWlEPTB;MD6yOVc4PyEQvF2=	Mn2zV2FPT0WU
COLO-800	M3zpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPVbpRKSzVyPUCuNlU5OTJizszN	MXjTRW5ITVJ?
LU-134-A	NHLPOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHUTWM2OD1yLkK2NVM3KM7:TR?=	MkDrV2FPT0WU
NCI-H1155	NVvuOWlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TmNmlEPTB;MD6yOlE3OiEQvF2=	NGrpV\|dUSU6JRWK=
MFM-223	M4\LWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITaSZdKSzVyPUCuNlY{PjNizszN	Ml3EV2FPT0WU
HTC-C3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlmzTWM2OD1yLkK2OVA3KM7:TR?=	M17yenNCVkeHUh?=
HCT-116	Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLmdFRpUUN3ME2wMlI3PTl7IN88US=>	Mnm2V2FPT0WU
Ca-Ski	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMk[2O\|gh\|ryP	Mn23V2FPT0WU
SBC-1	M{PrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnrTWM2OD1yLkK2O\|QzKM7:TR?=	NH3Fcm1USU6JRWK=
NB69	NXXRTZRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fUWmlEPTB;MD6yO\|A5PyEQvF2=	NEHMdI1USU6JRWK=
J82	NEj0RYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvqTWM2OD1yLkK3NlY2KM7:TR?=	MYDTRW5ITVJ?
U-118-MG	NYi2c5p2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk[3TWM2OD1yLkK3OVc6KM7:TR?=	MkDKV2FPT0WU
NCI-H1355	M33Cemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGW2OItKSzVyPUCuNlgxPzRizszN	NF;Yco5USU6JRWK=
NCI-H1048	NGm0cJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Xle2lEPTB;MD6yPFk2PiEQvF2=	NHm0R2NUSU6JRWK=
SW954	M1;XR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfETWM2OD1yLkK5NlI4KM7:TR?=	M3nEO3NCVkeHUh?=
NMC-G1	NYfsNnduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Sw[GlEPTB;MD6yPVI4PyEQvF2=	Mon6V2FPT0WU
SW1710	NEfNbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nWOmlEPTB;MD6yPVQ6PCEQvF2=	NFP6WZhUSU6JRWK=
KY821	MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXHfnNyUUN3ME2wMlI6QDd{IN88US=>	MVzTRW5ITVJ?
HCC38	NIDrUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnZTWM2OD1yLkOwNFc5KM7:TR?=	NHn0[41USU6JRWK=
NCI-SNU-5	NWfm[lEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrsXGJKSzVyPUCuN\|A2PCEQvF2=	MlLpV2FPT0WU
ES8	MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\qeWhUUUN3ME2wMlMxPzh2IN88US=>	MXPTRW5ITVJ?
COLO-792	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTke3VYUUN3ME2wMlMyOjVzIN88US=>	M1;OWnNCVkeHUh?=
BFTC-905	NGPMc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHFTWM2OD1yLkOxOVIyKM7:TR?=	NVHseldYW0GQR1XS
ChaGo-K-1	NEC1OI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHKTWM2OD1yLkOxO\|E2KM7:TR?=	MUTTRW5ITVJ?
Daoy	M13KbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrWTWM2OD1yLkOxO\|I{KM7:TR?=	M{TNSnNCVkeHUh?=
SJSA-1	M1zFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfjOVdKSzVyPUCuN\|E5PDdizszN	NF;QVllUSU6JRWK=
KNS-62	NV\le2ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYH1VFR6UUN3ME2wMlMzODh6IN88US=>	NW\jSFd3W0GQR1XS
CAKI-1	NI\TeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfjTWM2OD1yLkOyNVEyKM7:TR?=	M{m1VnNCVkeHUh?=
UACC-62	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorvTWM2OD1yLkOyNlI4KM7:TR?=	M4r3e3NCVkeHUh?=
HuCCT1	Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwM{KyPFMh\|ryP	NUHFNXVOW0GQR1XS
CTB-1	M1jkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzRd3hKSzVyPUCuN\|I4PTNizszN	NEP3Rm1USU6JRWK=
NTERA-S-cl-D1	M3y2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwM{K4N\|Yh\|ryP	MXfTRW5ITVJ?
T-24	NHjnO\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\MTWM2OD1yLkOzNVU6KM7:TR?=	MoTIV2FPT0WU
KYSE-70	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3X3ZWlEPTB;MD6zN\|I5OyEQvF2=	MX3TRW5ITVJ?
SW626	M2rDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTLTWM2OD1yLkOzOVMzKM7:TR?=	Mn3oV2FPT0WU
LB996-RCC	NHXhNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zlTmlEPTB;MD6zN\|YyQSEQvF2=	NXrJSmk{W0GQR1XS
DMS-273	NFLGXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXCeIhYUUN3ME2wMlM{QTF4IN88US=>	NF\0bZZUSU6JRWK=
SW1783	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\mOmhUUUN3ME2wMlM{QTl5IN88US=>	MV3TRW5ITVJ?
KU812	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHDTWM2OD1yLkO0NFM5KM7:TR?=	MVjTRW5ITVJ?
HSC-2	NF\QWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXjS3B6UUN3ME2wMlM1ODV\|IN88US=>	M2n0TnNCVkeHUh?=
A3-KAW	NGDn[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDNTG9KSzVyPUCuN\|QyPjJizszN	MV7TRW5ITVJ?
COLO-684	NV\xV2NNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTITWM2OD1yLkO0OVAyKM7:TR?=	NGLpfWpUSU6JRWK=
NCI-H2405	MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwM{S2N\|Eh\|ryP	Mmm1V2FPT0WU
NCI-H2228	NWDHXopTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXS1XIlDUUN3ME2wMlM2OzV5IN88US=>	MX;TRW5ITVJ?
NB13	NWPKZpBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LEVGlEPTB;MD6zOlgzQSEQvF2=	M3v2WnNCVkeHUh?=
no-11	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHlc21KSzVyPUCuN\|Y6PSEQvF2=	MoHCV2FPT0WU
DK-MG	MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;yfGQzUUN3ME2wMlM4OTh6IN88US=>	MU\TRW5ITVJ?
NBsusSR	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnRTWM2OD1yLkO3Nlg2KM7:TR?=	NXviUVVvW0GQR1XS
KP-N-YS	M2njbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PMRmlEPTB;MD6zO\|Q3OyEQvF2=	M4HoV3NCVkeHUh?=
CFPAC-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwM{e1NVgh\|ryP	M3XUb3NCVkeHUh?=
KARPAS-45	NI\VRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwM{e4OlIh\|ryP	NWPvN5h6W0GQR1XS
NCI-H1793	MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfoNXB4UUN3ME2wMlM5PTFizszN	NWnNTFBXW0GQR1XS
HCE-T	M{nkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXW2Z29pUUN3ME2wMlM5PjB\|IN88US=>	MX;TRW5ITVJ?
NCI-H520	NWT3S3hVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\QPG1KSzVyPUCuN\|g4ODNizszN	NGS4V21USU6JRWK=
HCC2157	NITuRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwM{i3PFEh\|ryP	NV3YT3h1W0GQR1XS
EW-18	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwM{i5OFEh\|ryP	M3rFbnNCVkeHUh?=
RO82-W-1	NFuxeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFq0[o1KSzVyPUCuN\|k3QTlizszN	MUTTRW5ITVJ?
HuP-T3	MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEe1cYNKSzVyPUCuOFAyPDNizszN	NEHTPFRUSU6JRWK=
PANC-10-05	MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwNEGxO{DPxE1?	NX;YdFhlW0GQR1XS
NCI-H1703	MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPhUmhKSzVyPUCuOFE1PDZizszN	Mk\iV2FPT0WU
TE-10	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwNEG0OFch\|ryP	NUTnR2JnW0GQR1XS
HOS	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2r6[GlEPTB;MD60NVY5OiEQvF2=	MWDTRW5ITVJ?
LN-405	NGjFcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXTRYJKSzVyPUCuOFE3QDdizszN	NYfHcFFHW0GQR1XS
A427	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfsTWM2OD1yLkSxPVgyKM7:TR?=	MUfTRW5ITVJ?
CAL-12T	M3ewUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nk[GlEPTB;MD60Nlc5KM7:TR?=	MVzTRW5ITVJ?
SW756	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDld3FKSzVyPUCuOFQyQDNizszN	MnvCV2FPT0WU
YAPC	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LscmlEPTB;MD60OVA5KM7:TR?=	NEnuPGtUSU6JRWK=
GOTO	M2rHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnnbItKSzVyPUCuOFUyPiEQvF2=	Mke5V2FPT0WU
C3A	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwNEW0N\|ch\|ryP	M17DNXNCVkeHUh?=
UM-UC-3	NIrGO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwNEW0O{DPxE1?	M{HNfnNCVkeHUh?=
NCI-H1573	NHH3WoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3f4dGlEPTB;MD60OVU3QSEQvF2=	NIPNSoVUSU6JRWK=
LS-411N	M2HLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwNE[1Nlch\|ryP	NGqwUnFUSU6JRWK=
COR-L23	MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nYb2lEPTB;MD60Olc3PCEQvF2=	NYPWfVBuW0GQR1XS
HCE-4	NXniWXlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLIfnBvUUN3ME2wMlQ4PDR4IN88US=>	M3mzV3NCVkeHUh?=
NCI-H2291	NEnLNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3FcY5KSzVyPUCuOFc5QTZizszN	NYLiTFlPW0GQR1XS
A101D	M3S3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLDTWM2OD1yLkS4NFU{KM7:TR?=	NG\idIpUSU6JRWK=
HT-3	NXPZdmFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUD6SnhWUUN3ME2wMlQ5OjF5IN88US=>	NVrEblR4W0GQR1XS
HOP-62	MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfKb29KSzVyPUCuOFk5PjVizszN	MWXTRW5ITVJ?
PC-3	NYjMXGF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDrTWxXUUN3ME2wMlUyPTB5IN88US=>	MnKxV2FPT0WU
CTV-1	MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwNUK2Olkh\|ryP	NXz4[401W0GQR1XS
PANC-08-13	NF7FRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1P4RmlEPTB;MD61N\|E4PyEQvF2=	MW\TRW5ITVJ?
CAL-120	NFLzTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojDTWM2OD1yLkWzN\|k6KM7:TR?=	NIrXNlJUSU6JRWK=
UMC-11	NYPmbIpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37qdWlEPTB;MD61OVI{PCEQvF2=	MVjTRW5ITVJ?
MSTO-211H	M{f3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jocmlEPTB;MD61OVc3OiEQvF2=	NHrpb5NUSU6JRWK=
NCI-H2126	M1KxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH21VIFKSzVyPUCuOVY5OTVizszN	MknuV2FPT0WU
SNU-C2B	M2iwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTqTWM2OD1yLkW3PVc4KM7:TR?=	NGTXWo5USU6JRWK=
DBTRG-05MG	MkLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwNUiwOVMh\|ryP	NIHreZVUSU6JRWK=
MKN1	NXf4cYJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PEbGlEPTB;MD61PFc5OyEQvF2=	MV3TRW5ITVJ?
ES3	MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwNUmxNlQh\|ryP	MVvTRW5ITVJ?
OVCAR-3	NITwZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYn3N3RjUUN3ME2wMlU6OzRzIN88US=>	M3\FcXNCVkeHUh?=
ACHN	M4fXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwNkC1Olkh\|ryP	M4HmbnNCVkeHUh?=
SW872	M3jLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHSXlc1UUN3ME2wMlYxPzZ\|IN88US=>	NHzqdoRUSU6JRWK=
CP66-MEL	MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\IUZJKSzVyPUCuOlA6PjlizszN	MUnTRW5ITVJ?
NCI-H661	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnlXVBKSzVyPUCuOlEyODRizszN	NVKxfYhwW0GQR1XS
UACC-893	NXnQ[W9qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLETWM2OD1yLk[zOlgyKM7:TR?=	NUjOToJRW0GQR1XS
JVM-3	MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorUTWM2OD1yLk[zPFA1KM7:TR?=	MV3TRW5ITVJ?
SF268	NU\MTYg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVWxXFA5UUN3ME2wMlY1OzR7IN88US=>	NXmzOZZSW0GQR1XS
OCI-AML2	NVG5UmlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDobnRnUUN3ME2wMlY2Ozl5IN88US=>	M4PHbHNCVkeHUh?=
RPMI-8226	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULBNpB5UUN3ME2wMlY3OzJ\|IN88US=>	M2niN3NCVkeHUh?=
MKN28	M{XBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TmWGlEPTB;MD62OlYzPCEQvF2=	MlHUV2FPT0WU
MDA-MB-453	M2HHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfzNFJjUUN3ME2wMlY4OThizszN	NXq2T\|hUW0GQR1XS
BV-173	MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwNki2O\|kh\|ryP	NWTodoZJW0GQR1XS
NCI-H358	MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHmW49NUUN3ME2wMlY5PzJ4IN88US=>	NGftPFlUSU6JRWK=
NCI-H1651	MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7SNIVvUUN3ME2wMlch\|ryP	Mk\DV2FPT0WU
MDA-MB-415	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;ZTWM2OD1yLkewPFI6KM7:TR?=	MWHTRW5ITVJ?
8305C	NXvYZ29VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3vWWJKSzVyPUCuO\|I1QThizszN	MoezV2FPT0WU
EFM-19	M4Pk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XxPGlEPTB;MD63N\|Y4OSEQvF2=	MYnTRW5ITVJ?
RERF-LC-MS	NFPnWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXlTWM2OD1yLke0OlE{KM7:TR?=	NYDXPGxGW0GQR1XS
A388	M3z6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPoZlVpUUN3ME2wMlc3PDZ5IN88US=>	NYW1bmpyW0GQR1XS
GI-ME-N	NWDlSYNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2KyOmlEPTB;MD63O\|I{PSEQvF2=	MX\TRW5ITVJ?
IGR-1	NGTJO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYC3NHFCUUN3ME2wMlc6ODR\|IN88US=>	MX7TRW5ITVJ?
LNCaP-Clone-FGC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnuNmhqUUN3ME2wMlgxODB2IN88US=>	MYfTRW5ITVJ?
SK-MEL-3	M3jSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;BVVdMUUN3ME2wMlgyPTB6IN88US=>	M3TGR3NCVkeHUh?=
UACC-257	M{DNTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTBwOEKyN\|Eh\|ryP	NVHPfHBrW0GQR1XS
OE33	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTBwOEWxNFEh\|ryP	M3O5fHNCVkeHUh?=
QIMR-WIL	M2H2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwOEWxOFEh\|ryP	MU\TRW5ITVJ?
NCI-H2009	M1XsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jWOGlEPTB;MD64OVMyOSEQvF2=	M2T2d3NCVkeHUh?=
NCI-H522	M3P6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHJTWM2OD1yLki3O\|g{KM7:TR?=	NVH2cIkzW0GQR1XS
Saos-2	M3L2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1:5Z2lEPTB;MD64O\|g4OSEQvF2=	M4PMUXNCVkeHUh?=
NB17	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\3S3VUUUN3ME2wMlg5ODJ3IN88US=>	NIO2dJZUSU6JRWK=
D-392MG	NIjLWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGeyOYVKSzVyPUCuPFk{PTZizszN	NV\4O4J{W0GQR1XS
SHP-77	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MorrTWM2OD1yLkmwOFg2KM7:TR?=	MmXyV2FPT0WU
SK-MEL-30	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;DTWM2OD1yLkmxNVg2KM7:TR?=	MnTRV2FPT0WU
GCIY	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDFTWM2OD1yLkmxPFQ{KM7:TR?=	MYHTRW5ITVJ?
HCC70	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPYUHBKSzVyPUCuPVIxPTlizszN	MUjTRW5ITVJ?
LU-65	M4DCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXRV4JKSzVyPUCuPVI2QTFizszN	NWjYfJBPW0GQR1XS
NCI-H1563	NYLnV5IxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzhdmlKSzVyPUCuPVQ5PjVizszN	MlrOV2FPT0WU
KURAMOCHI	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHsVY1xUUN3ME2wMlk2OTl{IN88US=>	NWTT[2FwW0GQR1XS
PA-1	MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwOUW0NlQh\|ryP	MlLCV2FPT0WU
NOS-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHDTmZKSzVyPUCuPVc1QDlizszN	MkWwV2FPT0WU
NCI-H69	MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVz2N3gyUUN3ME2wMlk4PjN2IN88US=>	M2S1O3NCVkeHUh?=
KYSE-450	M13yUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHy4UWFKSzVyPUCuPVg3OjZizszN	MVLTRW5ITVJ?
8505C	NUfZdVhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWW0VnNmUUN3ME2wMlk6QTh{IN88US=>	M37RO3NCVkeHUh?=
TGBC24TKB	NXezTVNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TKNGlEPTB;MT6wNFA5PCEQvF2=	M3PUOXNCVkeHUh?=
PFSK-1	M1j2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF22dYFKSzVyPUGuNFE1OjhizszN	NVHsVmtTW0GQR1XS
EKVX	NHv6VHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnmNFRmUUN3ME2xMlA{OTJzIN88US=>	MWnTRW5ITVJ?
RCM-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\s[olzUUN3ME2xMlA2PTB5IN88US=>	M3P6Z3NCVkeHUh?=
SW900	MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljTTWM2OD1zLkC3PFMh\|ryP	Mm\xV2FPT0WU
D-542MG	NXTvN2JtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTFwMEe4OVUh\|ryP	MYjTRW5ITVJ?
SK-PN-DW	NVXVPHN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTFwMUCwOVYh\|ryP	MV\TRW5ITVJ?
NCI-H727	M3;FOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTFwMUCxOVQh\|ryP	NETVfI1USU6JRWK=
SW837	MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfhfWhKSzVyPUGuNVA6PTRizszN	M2rJVXNCVkeHUh?=
BT-20	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPMcJRRUUN3ME2xMlEyOjB2IN88US=>	MnTiV2FPT0WU
RH-18	NEmxXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NID2ZZpKSzVyPUGuNVMyODNizszN	M3e2PHNCVkeHUh?=
TE-12	MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LOb2lEPTB;MT6xN\|M{OyEQvF2=	NX\ZNWl[W0GQR1XS
NB10	M{T2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zVWmlEPTB;MT6xN\|M1PCEQvF2=	NXLwfZljW0GQR1XS
AU565	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfJdJRbUUN3ME2xMlE2QTd\|IN88US=>	NXPtToRPW0GQR1XS
OAW-42	MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTmfWFrUUN3ME2xMlE5OzB4IN88US=>	NYrkbHNIW0GQR1XS
DJM-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\h[WlEPTB;MT6xPVg5OSEQvF2=	M4D1dnNCVkeHUh?=
HH	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnP0TWM2OD1zLkKzPFMyKM7:TR?=	NG\vZW9USU6JRWK=
LAMA-84	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLzTWM2OD1zLkK3N\|k1KM7:TR?=	NUnHVnNPW0GQR1XS
KNS-42	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnqzTWM2OD1zLkOwNlk3KM7:TR?=	MXvTRW5ITVJ?
NCI-H2052	NYXPNmdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXYTZZKSzVyPUGuN\|A2ODdizszN	NHLoZW5USU6JRWK=
MLMA	NFm5TmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTCO2RHUUN3ME2xMlMzPDB5IN88US=>	MVLTRW5ITVJ?
NB12	MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnYbJRKSzVyPUGuN\|U3OzZizszN	MYTTRW5ITVJ?
NCI-H1838	M2\Sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXBW5NyUUN3ME2xMlM3OzB4IN88US=>	Ml20V2FPT0WU
NCI-H526	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfLSmpUUUN3ME2xMlM4QDV\|IN88US=>	MV\TRW5ITVJ?
LS-123	Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XIT2lEPTB;MT6zPVA6PCEQvF2=	MWTTRW5ITVJ?
HDLM-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4r3S2lEPTB;MT6zPVI4OSEQvF2=	MkDLV2FPT0WU
MC-IXC	MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFn2O2tKSzVyPUGuOFI{PzFizszN	NF;HT3BUSU6JRWK=
HCT-15	M1joPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHT[lZKSzVyPUGuOFMxPjhizszN	MUnTRW5ITVJ?
NCI-H596	M3\we2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLPTWM2OD1zLkS1NFYyKM7:TR?=	MmL5V2FPT0WU
ZR-75-30	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTUTWM2OD1zLkS3NFgzKM7:TR?=	MVvTRW5ITVJ?
A704	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jKTGlEPTB;MT62OlU3OyEQvF2=	M{fC[3NCVkeHUh?=
OVCAR-4	M3HEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmGwTWM2OD1zLk[5OlA4KM7:TR?=	MXLTRW5ITVJ?
SW1417	NYXuSWt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXCbWgxUUN3ME2xMlczQDR7IN88US=>	MWPTRW5ITVJ?
CAS-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M362TGlEPTB;MT63N\|k{PiEQvF2=	NHLEO\|RUSU6JRWK=
IST-SL1	NVLmc3ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2e5S2lEPTB;MT63PVc2QSEQvF2=	MkTlV2FPT0WU
A253	Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV35U\|Z5UUN3ME2xMlgzOjN7IN88US=>	Mle4V2FPT0WU
EW-16	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHNZXFMUUN3ME2xMlgzQDd3IN88US=>	NIPFR4xUSU6JRWK=
SK-NEP-1	NYHRZ2xoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3oe\|RKSzVyPUGuPFY6QDhizszN	NXnLWGJoW0GQR1XS
NCI-H226	MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTFwOEmzOVkh\|ryP	M3LuS3NCVkeHUh?=
HOP-92	NYSzXWxzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTFwOU[wPVkh\|ryP	Mo\oV2FPT0WU
NCI-H441	M3H1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTJwMEKzN\|ch\|ryP	MWTTRW5ITVJ?
LU-139	NH3wRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33FWGlEPTB;Mj6wN\|EyPCEQvF2=	M13xVnNCVkeHUh?=
SJRH30	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWD4VohuUUN3ME2yMlA1OjV\|IN88US=>	M4f1XXNCVkeHUh?=
MG-63	NELueZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vydGlEPTB;Mj6xOFEyOSEQvF2=	MVTTRW5ITVJ?
NH-12	NYflWYt2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLOV5VKSzVyPUKuNVUxODZizszN	MY\TRW5ITVJ?
NB7	NEjM[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjnNnBKSzVyPUKuNVk3PzNizszN	MmXFV2FPT0WU
LB771-HNC	M2Tnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHnTmpKSzVyPUKuNlA2QTVizszN	MYrTRW5ITVJ?
HCC1569	NXO4bW9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\3[lNKSzVyPUKuNlQ2QDNizszN	MXnTRW5ITVJ?
D-283MED	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjYUYNDUUN3ME2yMlI1Pzh{IN88US=>	MVrTRW5ITVJ?
J-RT3-T3-5	M1rpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4X1b2lEPTB;Mj6yOVM2OSEQvF2=	M33tSXNCVkeHUh?=
ATN-1	NV;hRWVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTJwM{OwPFIh\|ryP	MmexV2FPT0WU
HCC1954	MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTJwM{S0NFgh\|ryP	MoHEV2FPT0WU
SCC-15	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHP[plKSzVyPUKuN\|k{OTJizszN	MnLVV2FPT0WU
COLO-668	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUK3eWt[UUN3ME2yMlQ{OiEQvF2=	MoCwV2FPT0WU
LB373-MEL-D	MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm[yTWM2OD1{LkW0Olc4KM7:TR?=	MXTTRW5ITVJ?
no-10	M{PLRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jtb2lEPTB;Mj61OFk1PyEQvF2=	NFr4NGNUSU6JRWK=
HT-1197	NVv5WVNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1[0fGlEPTB;Mj62N\|E5QCEQvF2=	NEfzVIRUSU6JRWK=
DU-145	MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zJUmlEPTB;Mj63PVE3OiEQvF2=	NX\4V3V6W0GQR1XS
SK-N-AS	M2Loe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3FWZc3UUN3ME2yMlg1Pjl{IN88US=>	M13H[HNCVkeHUh?=
MOLT-4	Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTJwOEWzNlIh\|ryP	MVXTRW5ITVJ?
EW-22	M4W4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLsTWM2OD1{LkmyPFQyKM7:TR?=	MnP0V2FPT0WU
DB	NE\zc\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHSyeGFKSzVyPUKuPVc4PTlizszN	M4X5PHNCVkeHUh?=
HL-60	NYLreJVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzxTWM2OD1\|LkC0N\|c3KM7:TR?=	NGryRXVUSU6JRWK=
SK-N-DZ	NH32RoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHP3dFJKSzVyPUOuNFUxPzVizszN	MnfqV2FPT0WU
NY	NYHoVXVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnmZ3lKSzVyPUOuNFg2PDJizszN	MULTRW5ITVJ?
T47D	M{Dz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTNwMUC1OVgh\|ryP	M16wOnNCVkeHUh?=
NCI-H2029	NWG0c244T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7qfVNkUUN3ME2zMlIzPDd5IN88US=>	M{DiPXNCVkeHUh?=
KARPAS-299	M4nCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTNwMk[wNlch\|ryP	NX60OYp3W0GQR1XS
KM-H2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Dn[GlEPTB;Mz6zNFY5KM7:TR?=	NV\2eVJtW0GQR1XS
CHP-134	M3e0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HnTWlEPTB;Mz60O\|M6KM7:TR?=	Mk\lV2FPT0WU
22RV1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnyT5JpUUN3ME2zMlQ6OTZ6IN88US=>	MYfTRW5ITVJ?
NB5	NHHlR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;TVmlEPTB;Mz61NFY5QSEQvF2=	NXTXb\|l4W0GQR1XS
CW-2	MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUW4[5FTUUN3ME2zMlU2OzF2IN88US=>	NETI[oNUSU6JRWK=
EFO-21	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\vTWM2OD1\|LkW2PVQh\|ryP	NYTGNWhnW0GQR1XS
HuH-7	NInDSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jRXWlEPTB;Mz61PFQyPCEQvF2=	MVXTRW5ITVJ?
ALL-PO	M{n6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnRfZlxUUN3ME2zMlYzOzN3IN88US=>	NGW1SHlUSU6JRWK=
EM-2	NX3PeHdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XYOmlEPTB;Mz62PVAyOSEQvF2=	NVricot2W0GQR1XS
KLE	M4juR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHDVnRKSzVyPUOuO\|MxOjlizszN	NETqUolUSU6JRWK=
NEC8	NYTJNY9FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HxUWlEPTB;Mz65NVgxQCEQvF2=	NH62b4FUSU6JRWK=
KP-N-YN	Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTNwOUO0O\|Yh\|ryP	NW\3WINoW0GQR1XS
SK-MEL-1	M4jXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzweVgxUUN3ME20MlA{PTF6IN88US=>	M3KwZXNCVkeHUh?=
CAL-54	NUSzXlFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXSb5dtUUN3ME20MlA2QTFizszN	MUfTRW5ITVJ?
MS-1	M2PKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HEbGlEPTB;ND6xOlE2PSEQvF2=	MmjJV2FPT0WU
NCI-H209	NWHQTpA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HIdGlEPTB;ND6yPVk6QSEQvF2=	NWPZNFduW0GQR1XS
NOMO-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXH4UnlTUUN3ME20MlMzOTNzIN88US=>	M3jnbnNCVkeHUh?=
RPMI-2650	MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDWTWM2OD12LkO2N\|I4KM7:TR?=	M1nXXXNCVkeHUh?=
NCI-H810	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1G2dGlEPTB;ND6zPVc{PiEQvF2=	M1rUOnNCVkeHUh?=
Ca9-22	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoP5TWM2OD12LkS1OlkyKM7:TR?=	NE\o[2JUSU6JRWK=
ES4	M1HzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTuXWRKSzVyPUSuOFcxQTVizszN	MUTTRW5ITVJ?
ES6	M4TGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorjTWM2OD12LkS5OlU4KM7:TR?=	M{fQWnNCVkeHUh?=
DMS-114	NY\WN5RqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\YTWM2OD12LkW0OlkyKM7:TR?=	M4\4VXNCVkeHUh?=
ONS-76	NXPTSY1{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTOTWM2OD12LkW3PVUh\|ryP	M2\0SnNCVkeHUh?=
K-562	NYf5eY1OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnSyTWM2OD12LkezPFE1KM7:TR?=	NEjSfoRUSU6JRWK=
MHH-NB-11	MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPsR5hKSzVyPUSuO\|U1PjFizszN	NW\FVI9FW0GQR1XS
Calu-3	Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4D5cWlEPTB;ND63PFU1QCEQvF2=	M3LIRXNCVkeHUh?=
HT55	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlT1TWM2OD12Lki0OVQ2KM7:TR?=	Mm\yV2FPT0WU
SK-N-FI	MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\PVXpKSzVyPUSuPFUxODlizszN	MXnTRW5ITVJ?
ES1	M{m1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXBTWM2OD12Lki2NFU4KM7:TR?=	NV\DUGhlW0GQR1XS
SF126	NFXEXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHCT2RUUUN3ME20Mlk{OTh2IN88US=>	NGL4Tm1USU6JRWK=
ES5	Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDROFJKSzVyPUWuNVI1OjdizszN	MU\TRW5ITVJ?
LoVo	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4e4OWlEPTB;NT6xOVg4OSEQvF2=	MonyV2FPT0WU
SNU-387	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHx[5RnUUN3ME21MlMzOzN7IN88US=>	MkmxV2FPT0WU
C8166	NGq1W29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2G2ZWlEPTB;NT6zOlM{QSEQvF2=	NX;BSXB2W0GQR1XS
LS-1034	MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTVwNEKzNFch\|ryP	NGH5[lJUSU6JRWK=
GR-ST	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETpSpZKSzVyPUWuOVIzODFizszN	M123UHNCVkeHUh?=
NCI-H1092	MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXWyRoZTUUN3ME21MlczQDR\|IN88US=>	NIrVVJJUSU6JRWK=
647-V	M3rFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml2xTWM2OD13Lke0O\|A3KM7:TR?=	M{LiSHNCVkeHUh?=
EW-13	M3[ySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF25RWZKSzVyPUWuO\|Y3OjdizszN	NUHaSmJ6W0GQR1XS
KGN	NWXDe5V4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXMTWM2OD14LkC5PVIyKM7:TR?=	M2PGTnNCVkeHUh?=
D-423MG	MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrpTWM2OD14LkSwNlg1KM7:TR?=	M3G2WnNCVkeHUh?=
ECC10	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTdwMUCxNFEh\|ryP	MVvTRW5ITVJ?
TE-5	M3v5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHsTWM2OD15LkSxNlk5KM7:TR?=	M1[1[3NCVkeHUh?=
P12-ICHIKAWA	MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jhUGlEPTB;Nz60OVUzOyEQvF2=	MlniV2FPT0WU
NCI-H82	MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGO1SHVKSzVyPUeuOFU4ODFizszN	Mo\vV2FPT0WU
NCI-H1993	NE\ZVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTdwOEOwOlMh\|ryP	NEHx[I9USU6JRWK=
RH-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\MXmlEPTB;Nz64OVI1PCEQvF2=	M37SZ3NCVkeHUh?=
SW948	MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTdwOU[wOFkh\|ryP	MVfTRW5ITVJ?
CAL-33	M2rYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\GcFk2UUN3ME23Mlk6QTN6IN88US=>	Mlr4V2FPT0WU
U-266	MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITmOVRKSzVyPUiuNVU4PzdizszN	NWO5VWViW0GQR1XS
CAL-72	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRThwMkCzNkDPxE1?	Mm\SV2FPT0WU
SNU-423	MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTlwM{[2OlYh\|ryP	NGHyVmtUSU6JRWK=
KG-1	NX;TNYh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV[5eohxUUN3ME25MlU5PDV4IN88US=>	Mlz2V2FPT0WU
HCC1395	MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3vN3FKSzVyPUmuPVI{PTJizszN	MUDTRW5ITVJ?
BE-13	NIjYXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfDTWM2OD1zMD64PFkzKM7:TR?=	Mmq4V2FPT0WU
MKN7	M3O5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmD1TWM2OD1zMD65O\|Y2KM7:TR?=	MYTTRW5ITVJ?
697	Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXe2UlJoUUN3ME2xNU4yPDd{IN88US=>	MXHTRW5ITVJ?
LU-135	NFrmcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFzLkKzNFch\|ryP	NYXaXoVYW0GQR1XS
ES7	NV3vWpBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\TXWlEPTB;MUGuN\|MyOyEQvF2=	MkXkV2FPT0WU
SK-HEP-1	M2XT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfJcFdKSzVyPUGxMlc3PDZizszN	NWX0ZVJFW0GQR1XS
BEN	NGPJNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTFzLki1NUDPxE1?	M121SnNCVkeHUh?=
NCI-H1770	Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTF{LkGyOkDPxE1?	NF3MNXBUSU6JRWK=
SW13	M4SxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1v6ZmlEPTB;MUKuNVU1OSEQvF2=	Ml[5V2FPT0WU
MZ1-PC	MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fhbWlEPTB;MUKuOVQ2OiEQvF2=	M4\uNXNCVkeHUh?=
Mo-T	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\yTWM2OD1zMj63OFIyKM7:TR?=	M{mwSHNCVkeHUh?=
HLE	M{fMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTF{LkiyNVUh\|ryP	NX3mUI9mW0GQR1XS
RCC10RGB	M{LnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\KWmlEPTB;MUOuOlcyKM7:TR?=	Mm\RV2FPT0WU
COLO-320-HSR	NE[1OZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vt[mlEPTB;MUOuO\|M5OSEQvF2=	MX;TRW5ITVJ?
BHT-101	MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PkSmlEPTB;MUOuPFM1PSEQvF2=	NEnEWm1USU6JRWK=
OCUB-M	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTmTWM2OD1zND6xOlAzKM7:TR?=	NVv4SGVSW0GQR1XS
MEG-01	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1v6dmlEPTB;MUSuN\|cxQCEQvF2=	MX\TRW5ITVJ?
RS4-11	NELEeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2e2RmlEPTB;MUSuO\|QzKM7:TR?=	NYT0cXB6W0GQR1XS
MN-60	MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nSTGlEPTB;MUSuO\|g6PCEQvF2=	MXnTRW5ITVJ?
NCI-H1304	NUGyenNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnybJBKSzVyPUG1MlA1OjVizszN	M1P2fHNCVkeHUh?=
Ramos-2G6-4C10	NI\wbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TEWGlEPTB;MUWuNFU5OSEQvF2=	MXTTRW5ITVJ?
NCI-H2342	M1vTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTF3LkKwOFQh\|ryP	NVnJe2FYW0GQR1XS
LAN-6	NHPPVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PsTWlEPTB;MUWuOFQyPCEQvF2=	M3LER3NCVkeHUh?=
JVM-2	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEP2VnVKSzVyPUG1MlU4PDhizszN	M1:ySXNCVkeHUh?=
P30-OHK	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTF4LkC2NVQh\|ryP	NWDMTIpYW0GQR1XS
C-33-A	NYDQeXlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTF4Lk[yNVQh\|ryP	NEi1V2ZUSU6JRWK=
RPMI-8866	NVjEXZozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4ruT2lEPTB;MU[uPFQ6PiEQvF2=	MVzTRW5ITVJ?
NCI-H630	NXHUV45FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjMbIhKSzVyPUG2Mlg2OzdizszN	NGrLOlFUSU6JRWK=
KYSE-140	NGHj[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjJTWM2OD1zNz6yNFI5KM7:TR?=	M1rDVXNCVkeHUh?=
T84	M4G1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HmbmlEPTB;MUiuPFY6PSEQvF2=	M13icXNCVkeHUh?=
KU-19-19	NELHZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TrPWlEPTB;MUiuPVYxQCEQvF2=	NIfjZ5ZUSU6JRWK=
BALL-1	NGTQOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmmwTWM2OD1zOT6zN\|k6KM7:TR?=	MknmV2FPT0WU
Calu-6	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTF7LkS5NkDPxE1?	MknwV2FPT0WU
EGI-1	NYHxXoF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnHT5Y5UUN3ME2xPU42QThizszN	MnHqV2FPT0WU
MFH-ino	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTF7Lke0OVQh\|ryP	NH;ySXBUSU6JRWK=
GB-1	MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFr6SZdKSzVyPUKwMlM2OzVizszN	NF;Tc49USU6JRWK=
NCI-H1693	NWrFNJI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTJyLk[1NFUh\|ryP	MYDTRW5ITVJ?
SW1116	NEjENXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXDTWM2OD1{MD65N\|YzKM7:TR?=	NHLseZRUSU6JRWK=
H-EMC-SS	M2P0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTJ{LkC0OUDPxE1?	NH;a[JpUSU6JRWK=
D-502MG	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWH4Z4lkUUN3ME2yNk45OjZzIN88US=>	M1LtNnNCVkeHUh?=
IA-LM	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HQ[GlEPTB;MkOuNlQ6OyEQvF2=	M{jxWnNCVkeHUh?=
SW1463	NE\zS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTJ\|Lke5JO69VQ>?	MVLTRW5ITVJ?
JAR	NVL5RXFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTJ2LkOyPVMh\|ryP	NYXCfJV[W0GQR1XS
HT	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLUTWM2OD1{ND60O\|U{KM7:TR?=	MYLTRW5ITVJ?
LCLC-103H	NY\URmpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XNNmlEPTB;MkSuPFQ1QSEQvF2=	MWfTRW5ITVJ?
SNU-449	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTSTWM2OD1{ND64O\|QyKM7:TR?=	NGjjPGlUSU6JRWK=
KE-37	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TiemlEPTB;MkWuNFkzQCEQvF2=	MUDTRW5ITVJ?
NCI-H1623	M1rC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjHeXpKSzVyPUK3MlE{ODNizszN	M13mbnNCVkeHUh?=
MOLT-13	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWC3WYFyUUN3ME2yO{4{PTF4IN88US=>	NUfkSGV3W0GQR1XS
COLO-741	M2HoNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTNzLkOzN\|Mh\|ryP	MlvDV2FPT0WU
NB6	NE[4cm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjIRVNKSzVyPUOyMlI5PzZizszN	M4fJO3NCVkeHUh?=
MOLT-16	NVzB[\|dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTN\|LkCwOVUh\|ryP	MljBV2FPT0WU
IST-MES1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGCwXZVKSzVyPUO0MlA2PDFizszN	M2GyR3NCVkeHUh?=
A4-Fuk	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7zVJc6UUN3ME2zOU4xPjZizszN	NHj5e\|dUSU6JRWK=
CAL-85-1	NYjMe5V[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vETWlEPTB;M{WuNlgyPyEQvF2=	NILrZZRUSU6JRWK=
CCRF-CEM	M2nweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXmelJKSzVyPUO3MlE2OzZizszN	MWnTRW5ITVJ?
HAL-01	MlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTN6LkS4PFkh\|ryP	NU[0dIJpW0GQR1XS
HEL	M4PCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEC5TXdKSzVyPUSzMlM1ODlizszN	MnHpV2FPT0WU
EW-1	NFS1VGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVH0ZmY1UUN3ME20N{41PzZ6IN88US=>	MlfWV2FPT0WU
MDA-MB-231	MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\U[2lEPTB;NEWuNVE6QSEQvF2=	NEXxN\|lUSU6JRWK=
ABC-1	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTR4Lki1N\|gh\|ryP	NEHvNHJUSU6JRWK=
NCI-H446	MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTR6LkWwOVgh\|ryP	NFnv[ZRUSU6JRWK=
MHH-PREB-1	M3PZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTR7Lk[wNFch\|ryP	MWHTRW5ITVJ?
DOHH-2	NI[3SHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\GSVZKSzVyPUS5MlY3PTZizszN	NFn2TXJUSU6JRWK=
GCT	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzTfZRKSzVyPUS5MlY6PzZizszN	MlfoV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; PubMed: 20090920 PLoS One Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control. EGFR / PDGFR / AKT / MAPK / c-RAS; PubMed: 18682579 Neuro Oncol 17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment. pAKT / pMAPK / pRb; PubMed: 18682579 Neuro Oncol The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment. Cleaved PARP / Survivin; PubMed: 18827603 J Thorac Oncol Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control. LATS1 / p-LATS1 / YAP / CTGF; PubMed: 25712415 J Cell Mol Med Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF. The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.	20090920 18682579 18827603 25712415
Immunofluorescence	STAT3; PubMed: 27279418 Mol Med Rep Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole. YAP / TAZ; PubMed: 25290150 PLoS One Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM). β-catenin / E-cadherin; PubMed: 25290150 PLoS One Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.	27279418 25290150
Growth inhibition assay	Cell viability; PubMed: 18682579 Neuro Oncol 17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.	18682579

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	- Collapse Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Ethanol	5 mg/mL (8.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00103272	Terminated	Drug: tanespimycin\|Drug: bortezomib	Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00098488	Terminated	Drug: tanespimycin\|Biological: rituximab	B-cell Chronic Lymphocytic Leukemia\|Prolymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00118248	Completed	Drug: tanespimycin	Recurrent Thyroid Cancer\|Stage IV Follicular Thyroid Cancer\|Stage IV Papillary Thyroid Cancer\|Thyroid Gland Medullary Carcinoma	National Cancer Institute (NCI)	December 2004	Phase 2
NCT00098423	Completed	Drug: tanespimycin\|Drug: cytarabine	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia With Excess Blasts in Transformation\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes	National Cancer Institute (NCI)	November 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Luminespib (NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 56 Publications

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 56 Publications

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)